Research programme: bisphosphocins - Lakewood Amedex
Alternative Names: Bisphosphocins; Nu 2; Nu 4; Nu 5; NuBiotics - Lakewood-Amedex; Nubiotics research programme - Oligos Etc.Latest Information Update: 28 May 2020
At a glance
- Originator Oligos Etc.
- Developer Lakewood Amedex
- Class Anti-infectives; Antibacterials; Antifibrotics; Nucleotides; Small molecules
- Mechanism of Action Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infections
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Infections in USA
- 24 May 2019 Lakewood Amedex has patent protection for bisphosphocin technology in World (Lakewood Amedex pipeline, May 2019)
- 24 May 2019 Lakewood Amedex plans an adaptive phase IIb trial for Urinary tract infections (IV) (Lakewood Amedex pipeline, May 2019)